Cyproterone Acetate and Ethinylestradiol Tablets 2mg/0.035mg (21tabs/box)

• Dossier: Ctd
• Transport Package: Free
• Specification: 2mg/0.035mg
• Trademark: Sinolead
• Origin: China
• Model NO.: tablets

Product Description

 

Basic Info.

 

Generic Name	Cyproterone Acetate And Ethinylestradiol Tablets 2mg/0.035mg
Strength	2mg/0.035mg
Packing	21tabs/box
Origin	China

Component:
This product is a compound preparation composed of 2mg cyproterone acetate and 0.035mg ethinylestradiol.

Character:

This product is light yellow sugar-coated tablets, white or quasi-white after removing the coating.

Indications:

Ethinestradiol cyproterone tablets can be used for oral contraception.
Ethoestrel cyproterone tablets are also used for the treatment of androgen-dependent diseases in women, such as acne, especially the obvious type, and acne with seborrhea or inflammation or nodular formation (papular pustule acne, nodular cyst acne), androgenic alopecia in women, mild hirsutism, and hyperandrogenic symptoms in patients with polycystic ovary syndrome.
 

Usage and dosage:

Take orally

Administration method

Ethinylestradiol should be taken regularly to achieve the therapeutic effect and the required contraceptive protection. Use of hormonal contraception should be discontinued. The dosing regimen for ethinylestradiol is similar to that commonly used in most combination oral contraceptives. The same medication rules must then be considered. When taken correctly, combined oral contraceptives have a failure rate of about 1% per year. Irregular use of ethinestradiol cyproterone tablets can lead to intermenstrual bleeding and may reduce the reliability of treatment and contraception.

How to take ethinestradiol cyproterone tablets

It must be taken with a small amount of liquid at about the same time every day in the direction indicated in the package. Take 1 tablet daily for 21 days. Withdrawal bleeding usually occurs 7 days after withdrawal and the next pack begins. Bleeding usually begins 2-3 days after the last pill of the cycle is taken, and the bleeding has not ended by the time the next box of pills is started.

How do I start taking ethinestradiol cyproterone tablets

· No previous use of hormonal contraceptives (past 1 month)

The medication should be started on the first day of a woman's natural menstrual cycle (i.e. the first day of menstrual bleeding). It can also be started on days 2-5, but it is recommended to add barrier contraception within the first 7 days of the first treatment cycle.

Switch from combined hormonal contraceptives (combined oral contraceptives /COC), vaginal rings, or transdermal patches

Women should preferably start taking estradiol cyproterone immediately after taking the last hormone-containing pill of the original COC, but at the latest at the end of the withdrawal period of the original COC or at the end of the use of hormone-free pills. If a vaginal ring or transdermal patch was originally used, women should preferably take ethinestradiol cyproterone tablets the day after removal, and at the latest before the next use begins.

Switch from progesterone only methods (pellets, injections, implants) or from the progesterone release intrauterine birth control system (IUS)

Change from pellets (implant or IUS should be on withdrawal day, injection should be on next injection day) to compound cyproterone acetate tablets at any time, but it is recommended that in all these cases, barrier contraception should be added during the first 7 days of administration.

Matters needing attention:

Epidemiological studies have shown that the use of combined oral contraceptives (COCs) is associated with an increased risk of arterial and venous thrombosis and thromboembolic diseases such as myocardial infarction, deep vein thrombosis, pulmonary embolism, and stroke. These events are rare.

The risk of venous thromboembolism (VTE) is highest within the first year of use. The risk increases when the COC is started or when the same or different COC is used again (with a discontinuation interval lasting 4 weeks or more). Data from a large prospective 3 cohort study. Most of the increased risk occurred in the first 3 months.

In general, use of low doses of estrogen (< 50μg ethinylestradiol) for COCs women. The risk of VTE is 2-3 times higher than in women who do not use COCs and are not pregnant, but the risk is lower than during pregnancy and childbirth.

VTE may cause death (1-2%).

VTE is characterized by deep static thrombosis and/or pulmonary embolism, which may occur during the use of all COCs.